J&J/Bayer’s Rivaroxaban Clinical Program Reports Few Liver Toxicity Cases

Oral Factor Xa inhibitor will be filed mid-year for prevention of venous thromboembolism in orthopedic surgery patients.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet